<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731117</url>
  </required_header>
  <id_info>
    <org_study_id>P170404J</org_study_id>
    <nct_id>NCT03731117</nct_id>
  </id_info>
  <brief_title>FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU</brief_title>
  <acronym>FURTHER</acronym>
  <official_title>FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic acute tubular necrosis (ATN) is one of the main cause of acute kidney injury (AKI)
      in intensive care units (ICU). Sepsis and cardio-pulmonary bypass (CPB) are major providers.
      There is no validated tool to predict the evolution of AKI is ICU. Furosemide Stress Test
      (FST) may predict evolution of ATN-related AKI outside ICU in terms of progressive AKI, need
      for renal replacement therapy (RRT) or inpatient mortality with improved performance
      comparing to biomarkers. FST has not been validated in a prospective cohort in ICU in the
      settings of ischemic ATN. FURTHER aim to determine whether FST would be a useful tool to
      identify patients with slight to moderate AKI (KDIGO stage 1 and 2) who will evolve towards
      need for RRT following AKIKI (The Artificial Kidney Initiation in Kidney Injury ) delayed
      initiation criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FURTHER will enroll consecutive patients with AKI KDIGO stage 1 or 2 associated with a sepsis
      or following a cardiac surgery with CPB within 72h. Patients must have achieved a hemodynamic
      stabilization confirmed by clinical (no need for intravenous fluids, no significant variation
      of noradrenaline) and non-clinical (trans-thoracic echocardiography, passive leg rise or
      other validated tool) assessment. Included patients will receive 1 to 1.5 mg/kg of
      FUROSEMIDE. Urine output will be measured for 6 hours and compensated by the same volume of
      intravenous crystalloids. Need for RRT will be assess at 2-hour, 6-hour and daily up to day
      7, following the AKIKI-study delayed initiation arm criteria. FURTHER aim to evaluate FST in
      a well-defined prospective cohort of ischemic ATN-related AKI as predictor of need for RRT
      within a week.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-comparative, multicenter, study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for renal replacement therapy or death</measure>
    <time_frame>Before day 7</time_frame>
    <description>Need for renal replacement therapy will be define according to the AKIKI study (Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33). Need for RRT following AKIKI delayed initiation criteria.
FST performance will be compared to the need of RRT or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sensitivity</measure>
    <time_frame>3 hour after FST</time_frame>
    <description>FST will be positive if patient is non responder : 2-hour urine output &lt; 200mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 hour urine output</measure>
    <time_frame>6 hour after FST</time_frame>
    <description>measurement of urine out</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of effective renal replacement therapy</measure>
    <time_frame>daily up to day 7</time_frame>
    <description>Initiation of RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>daily up to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic safety: noradrenaline dose</measure>
    <time_frame>6 hour after FST</time_frame>
    <description>noradrenaline dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical safety: arterial pressure</measure>
    <time_frame>6 hour after FST</time_frame>
    <description>modification of systolic, diastolic or mean arterial blood pressure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>FST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FUROSEMIDE STRESS TEST</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection
1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period</description>
    <arm_group_label>FST</arm_group_label>
    <other_name>furosemide stress test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years old

          -  Hospitalized in ICU at day of inclusion

          -  Diagnosis of sepsis defined as proven or suspected infection and increase of the SOFA
             (Sequential Organ Failure Assessment) score by 2 points or more compared to basal OR
             Cardiothoracic surgery with CBP (Cardiopulmonary bypass) within 72 hours before
             inclusion

          -  Adequate cardiac output and volemia assessed by cardiac ultrasound, venous saturation
             in Oxygen (ScVO2) or ΔPP

          -  Hemodynamic stabilization : stable norepinephrine dosage (or &lt;20% variations) with no
             vascular filling during the last 3 hours

          -  AKI stage I or II in KDIGO classification

        Exclusion Criteria:

          -  Chronic Kidney Disease with glomerular filtration rate ≤ 30 ml/mn/1,73m2

          -  Obstructive AKI

          -  AKI stage III in KDIGO classification

          -  Known allergy to loop diuretics

          -  Contraindications to Furosemide

          -  FST not feasible within 12 hours of eligibility

          -  Previous AKI during the same hospitalization

          -  Pregnancy or breastfeeding women

          -  Subject under a legal protective measure

          -  No affiliation to a social regime or CMU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BOUADMA Lila, MD</last_name>
    <phone>01 40 25 77 03</phone>
    <phone_ext>33</phone_ext>
    <email>lila.bouadma@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VINCLAIR Camille, MD</last_name>
    <email>cvinclair@ch-cotebasque.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille VINCLAIR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthieu LEGRAND, MD</last_name>
      <phone>0631439665</phone>
      <email>matthieu.legrand@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lila BOUADMA, MD</last_name>
      <email>lila.bouadma@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Acute Kidney Injury</keyword>
  <keyword>Intensive care units</keyword>
  <keyword>AKI</keyword>
  <keyword>ICU</keyword>
  <keyword>FST</keyword>
  <keyword>FUROSEMIDE STRESS TEST</keyword>
  <keyword>RRT</keyword>
  <keyword>Renal Replacement Therapy</keyword>
  <keyword>sepsis</keyword>
  <keyword>Cardio-pulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Kidney Tubular Necrosis, Acute</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

